Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

May 28, 2024

https://www.globenewswire.com/news-release/2024/05/28/2888853/0/en/Pasithea-Therapeutics-to-Present-New-Preclinical-Data-Showing-PAS-004-Strongly-Inhibits-NRAS-Cancer-Cell-Lines-and-Demonstrates-Superior-Activity-in-Xenograft-Studies-at-2024-ASCO-.html

— PAS-004 inhibition of in vitro NRAS cell lines does not plateau in contrast to approved MEK inhibitors —

— PAS-004 inhibition of in vitro NRAS cell lines is greater than selumetinib and binimetinib and similar to trametinib —

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.